Role of N-glycosylation in trafficking and stability of human CLN5 by Moharir, Akshay
 
 
 
 
ROLE OF N-GLYCOSYLATION IN TRAFFICKING AND STABILITY OF HUMAN CLN5 
 
By 
AKSHAY MOHARIR 
B.S., Rashtrasant Tukdoji Maharaj Nagpur University, 2005 
M.S., Cochin University of Science and Technology, 2007 
 
 
 
A THESIS 
 
 
Submitted in partial fulfillment of the requirements for the degree 
 
 
MASTER OF SCIENCE 
 
Division of Biology 
College of Arts and Sciences 
 
 
KANSAS STATE UNIVERSITY 
Manhattan, Kansas 
 
2012  
 
 
 
         Approved by: 
 
Major Professor 
Dr. Stella Y lee 
 
 
 
 
ABSTRACT 
Neuronal Ceroid Lipofuscinoses (NCLs) are a group of lysosomal storage diseases that 
are characterized by accumulating autofluorescent lipopigments in cells. NCLs are a form of 
progressive neurodegenerative diseases with symptoms ranging from blindness, loss of speech 
and motor activities to ataxia and seizures. Patients do not live to adulthood in most cases, 
making it prevalent in children. Among the many genes that cause NCL, CLN5 leads to different 
forms of NCL (infantile, late infantile, juvenile, and adult). CLN5 protein resides in the lysosomes 
but its function has not been established. It is predicted to contain eight N-glycosylation sites,  
but the role of N-glycosylation on its function and trafficking has not been assessed.  
We analyzed the role of N-glycosylation on the transport and stability of human CLN5. 
We created N-glycosylation mutants of each site by changing the Asn to Gln and our analysis of 
these mutants show that all the eight N-glycosylation sites are used in vivo. We also report 
effects of abolishing individual N-glycosylation sites on the trafficking of CLN5. While the lack of 
glycosylation at some sites results in CLN5 being retained in the ER or Golgi, others do not 
affect CLN5 trafficking. Cycloheximide chase experiments show that one of the mutants 
(N401Q) in CLN5 leads to lower protein levels in cell pellets with an increased secretion 
compared to CLN5 wild type, while other mutations show differential stability in cell pellets. 
These results demonstrate that each N-glycosylation site plays a different role(s) in the stability, 
transport and/or function of CLN5.  
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BIOSYNTHETIC TRANSPORT PATHWAY 
Proteins play an important role in organelle dynamics and lend functional and structural 
characteristic features to the organelles they reside in. These proteins serve specific functions 
in these organelles and the loss of correct localization of these proteins can cause diseases. The 
process of delivering the proteins to their correct destination starts with their synthesis in the 
Endoplasmic Reticulum (ER). A newly synthesized protein has to be delivered to its specific 
cellular location which is accomplished by its transport through a series of membrane bound 
compartments. This transport process forms an essential part of intracellular protein trafficking 
which involves various adaptor proteins that aid in transport of cargo proteins to their 
destination (1). Mitochondrial proteins are an exception and do not follow this path. Instead, 
they are delivered to the mitochondria directly from the cytoplasm via other 
mechanisms/pathways. There are two basic pathways that have been broadly classified for 
protein trafficking: the biosynthetic pathway and the endocytic pathway.  The biosynthetic or 
the secretory pathway is involved in the transport of proteins from the ER to the Golgi and 
eventually to their final destination (lysosome, plasma membrane or secreted out of cell). In 
general, the process of moving proteins outward is termed anterograde transport (2, 3). This 
movement along the biosynthetic pathway is not random and involves various transporters and 
signal sequences that may be present in or acquired by the protein. Some proteins (such as 
lysosomal hydrolases) acquire the sorting signal through post translational modification in the 
Golgi. A generalized view of the biosynthetic pathway is shown in figure 1.1. The endocytic 
pathway on the other hand involves the movement of proteins from the plasma membrane to  
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Figure1.1- General view of the biosynthetic pathway. The biosynthetic pathway is shown in a 
simplified manner. A newly synthesized cargo protein destined for the lysosome lumen is 
trafficked from the ER to the Golgi, where it acquires the M6P tag in the cis Golgi which helps in 
recognition by the M6PR in TGN. The cargo protein in then transported to the endosomes by 
the M6PR where the M6PR dissociates from the cargo protein and recycles back to the TGN. 
The endosome matures to form the lysosome with the cargo protein in the lumen. PM – Plasma 
Membrane, LE- Late Endosome, EE- Early Endosome, TGN – Trans Golgi network, ER- 
Endoplasmic Reticulum, Rab5 – EE marker, Rab7- LE marker, Rab9-Lysosome marker, COPI – 
Coatomer protein complex-I, and COPII – Coatomer protein complex-II. 
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endosomes and then to the lysosomes for degradation. The process of moving proteins inward 
is generally termed retrograde transport. The endocytosed proteins become a part of the 
endocytic pathway. (4)  
Cargo Proteins 
The proteins being transported to their final destination through different pathways are 
termed cargo proteins. These cargo proteins can be soluble luminal proteins (e.g., lysosomal 
hydrolases) or transmembrane proteins (e.g., signaling receptors). Depending on the type of 
protein, different signals and adaptor/transport molecules aid in the proper targeting through 
organelles to their final destination. Usually soluble luminal proteins are recognized and bound 
by receptors that propel their transport (e.g., Mannose 6-phosphate receptors or M6PR) while 
membrane proteins contain signaling sequences that serve the same purpose. The luminal and 
transmembrane cargo proteins undergo various post translational modifications (in the ER, 
Golgi and/or lysosomes) that can serve different purposes. The most common modifications 
include glycosylation which are of two prevalent types. Glycosylation on Asn is termed N-linked 
glycosylation or N-glycosylation and starts in the ER. Another type of glycosylation is on Ser/Thr 
residue (termed O-linked glycosylation) which normally occurs in the Golgi.  In addition, 
glycosylated proteins undergo modifications on their N- or O-linked glycans (e.g., 
phosphorylation on mannose, and sialylation) (5). These modifications serve various functions 
including proper recognition of the cargo proteins by their transporters. In addition, some 
modifications (N- and O-Glycosylation) protect the cargo protein from being cleaved or 
degraded (e.g., lysosomal luminal proteins are protected from lysosomal hydrolases). These 
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modifications can either be removed once the cargo protein reaches its destination (e.g., 
Mannose 6-Phosphate) or remain unchanged (e.g., N-glycosylation).  
Transport Machinery 
The exit of luminal or transmembrane proteins from the ER involves their concentration 
into vesicles that are coated with Coatomer protein complex II (COPII) (6). Transmembrane 
cargo proteins exiting the ER contain an ER exit sequence which enables an organized exit (7, 8). 
These signals can be either di-acidic (YTDIE), di-basic (RR) or di-hydrophobic (FF and LV). The 
components of COPII recognize these motifs and bind them, enabling their transport out of the 
ER and to the Golgi (4, 9). COPII recruitment to the ER exit site is propelled by the activation of 
SAR1 (a small GTPase) (4). Some proteins (soluble luminal proteins) that need to be retained in 
the ER lumen are also transported to the Golgi as part of the bulk flow, but they contain an ER 
retrieval signal at the C- terminal (KDEL) which aids in their retrieval from the Golgi to the ER 
(10).  Type I membrane proteins of the ER contain a different type of retrieval signal (KKXX) that 
enables them to be retrieved to the ER (11). The ER-Golgi intermediate complex (ERGIC) is an 
essential location for retrieval of ER resident proteins (12) . This retrograde transport of 
proteins is mediated by COPI coated vesicles which are recruited similar to COPII by another 
small GTPase called ARF1 (12). 
Once the cargo proteins leave the ER, they move to the Golgi. The Golgi has a stack like 
structure consisting of cis, medial and trans compartments/cisternae with the cis towards the 
ER and trans facing the plasma membrane (PM). The cargo within the Golgi is thought to 
progress through the different stacks and eventually bud off from the trans Golgi. The model 
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currently accepted which explains the maturation of Golgi stacks is the cisternal maturation 
model. This model proposes that the budding vesicles from ER fuse to form the new cis 
cisternae while the old cis cisternae matures into the medial cisternae and the medial cisternae 
to the trans cisternae. The Trans Golgi network (TGN) acts as a hub for various post 
translational modifications and for sorting proteins for their final destination (5). The transport 
of cargo proteins from the Golgi to endosomes or PM occurs via small vesicles that bud from 
the TGN (donor) and merge with acceptor compartments. The most common coat protein that 
aids in transport via vesicles is clathrin. The vesicles that bud from the Golgi are coated with 
clathrin and it is interesting that only the last cisternae in the TGN have a clathrin coat while the 
earlier cisternae have different coat proteins (13). This might be an indication of differential 
trafficking phenomena in different cisternae of the TGN. Since transport to the endosomes is 
mediated by clathrin coated vesicles/ tubules, the last cisternae of the TGN might be involved in 
this process while other earlier cisternae may function in sorting proteins to other 
compartments or destinations. 
Exiting the Golgi or the TGN also involves specific signals and adaptors similar to or more 
complex than ER exit. The next destination after TGN in the biosynthetic pathway is usually the 
PM or endosome (14). The best examples of cargo proteins sorted from the TGN to the 
endosomes based on their signals are lysosomal hydrolases that have mannose 6-phosphate 
(M6P) residues on them.  These M6P residues are recognized by either cationic-dependent (CD-
M6PR) or -independent (CI-M6PR) mannose 6- phosphate receptors to target the cargo protein 
to the endosomes.  The cargo receptors in the TGN can utilize two types of signals for 
transporting cargo to the endosomes. One type of signal is present in the cytoplasmic domain 
8 
 
of the cargo receptor and consists of sequences that bind to AP1 (an adaptor complex of the 
TGN) (15). The other type of signal that is utilized by proteins such as β-secretase and sortilin  is 
DXXLL. This signal is recognized by GGA (Golgi localized, γ-ear containing, ADP ribosylation 
factor (ARF)-binding protein) adaptors (14). AP1 and GGA adaptors aid in vesicle formation and 
transport to the endosomes. 
The endosomes are an integral part of the endocytic pathway as well as the biosynthetic 
pathway.  Different forms of endosomes have been observed that undergo maturation and 
eventually fuse with the lysosomes. Lysosomal proteins (luminal and membrane) traffic from 
the TGN to the lysosome via endosomes (16). Endosomes can be early endosomes (EE) or late 
endosomes (LE). The late endosomes fuse with lysosomes to form intermediates called 
endolysosomes that eventually mature into lysosomes. The EE and LE can be distinguished by 
different markers, mainly belonging to the Ras superfamily of Rab GTPases. The Rab5 is 
characteristic marker of EE which switches to Rab7 in the LE and eventually to Rab9 in the 
lysosomes (17, 18).  
Lysosomal membrane cargo proteins have sorting motifs that are highly conserved and 
adaptor proteins recognize these motifs and bind to them. An example is the family of tyrosine 
based motifs YXXφ (X is any amino acid (aa) and φ is an aa with a bulky hydrophobic side chain) 
(19). These motifs have been shown to interact with all known adaptor complexes by yeast 
two-hybrid studies (20-23). The YXXφ motifs are known to be involved in the sorting to 
endosomes and lysosomes from the TGN and from PM to the TGN (19). Another family of 
motifs which is involved in similar functions as YXXφ is the dileucine based motifs. These motifs 
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are recognized by adaptor proteins AP-1, AP-2 and AP-3 (24).  These dileucine motifs are 
surrounded by acidic residues which are critical for their functioning (25).  
Lysosomal acid hydrolase transport 
The best studied examples of lysosomal/endosomal protein transport are lysosomal acid 
hydrolases. Soluble lysosomal proteins have their signal peptide cleaved as they enter the ER 
after which they undergo N-glycosylation where a preformed oligosaccharide core                       
(Glc3Man9GlcNac2) is added onto the asparagine residue within the consensus sequence N-X-
S/T (X is any aa residue except Pro or Asp).  This modification can be very important in 
protecting the hydrolases from being cleaved in the acidic environment, in addition to 
stabilizing the protein as well as help in sorting and transport (26). Once these soluble 
lysosomal proteins leave the ER and arrive in the Golgi, further modifications take place on the 
oligosaccharide that was added in the ER. The sugars are either trimmed or further addition of 
complex sugars can take place (e.g., fucose or N-acetyl neuraminic acid) or there is 
phosphorylation of select mannose residues (M6P). The M6P tag is added by the action of two 
enzymes – GlcNac-1-phosphotransferase and uncovering enzyme (UCE) (27-29). M6P receptors 
(M6PR) bind to the M6P in the TGN and transport the proteins to the endosomes where the 
acidic pH causes them to dissociate from their cargo. The hydrolases are then transferred onto 
late endosomes and lysosomes. The M6PRs recycle back to the TGN to bind fresh cargo 
proteins (30, 31). As mentioned before, there are two types of M6PRs – CI-M6PR and CD-M6PR. 
It has been shown that in mice lacking CD-M6PR or CI-M6PR, the cells utilize other mechanisms 
to target the proteins properly to the lysosomes (32). There have been several alternative 
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receptors that have been reported to carry out similar functions as the M6PR. Sortilin has been 
suggested to be an alternative as it is involved in the transport of acid sphingomylinase and 
prosaposin to the lysosomes (33, 34).  Another receptor, lysosomal integral membrane protein 
type 2 (LIMP-2) is involved in the lysosomal targeting of β-glucocerebrosidase (35).   Sorting and 
trafficking of lysosomal hydrolases from the TGN is mediated by clathrin/ AP1 coated vesicle 
formation (25) and ARF1 is responsible for the recruitment of AP1 to the TGN membrane (36, 
37). AP1 also plays a role in the process of retrograde transport from endosomes to TGN (38).  
 
LYSOSOMAL STORAGE DISEASES (LSD) 
Lysosomal storage diseases (LSD) are caused by defects in lysosomal protein function(s) 
or their trafficking, resulting in the accumulation or buildup of different kinds of material within 
the lysosomes. Lysosomes contain almost 50-60 soluble hydrolases (39) in addition to integral 
membrane proteins (40). An example of LSD, Gauchers disease is caused by defects in the 
transport of β-glucocerebrosidase (β-Glc).  The transport of β-Glc to the lysosomes is 
dependent on LIMP2 (35) and mutations or deletion of LIMP2 leads to reduced activity of β-Glc 
(41) as its transport to the lysosome is impaired. Mutating proteins involved in the 
multivesicular body (MVB) pathway also causes trafficking problems as has been shown in a 
recent study in yeast which leads to change in the vacuolar pH (42). The maintenance of low pH 
is essential for the functioning of lysosomes because it aids in various processes such as loading 
of neurotransmitters onto vesicles and lysosomal hydrolase maturation (43, 44). Apart from 
that, the low pH is necessary for the release of protein cargo from the M6PRs and increasing 
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the pH can lead to the accumulation of M6PRs in the endosomal compartments and not 
recycling to the TGN (45).            
             Among the best studied LSD caused by defective transport of proteins to lysosomes is 
the I-cell disease or mucolipidosis II (ML II).  The disease is caused due to a faulty M6PR system 
which results in defective transport of lysosomal enzymes.  The defect is in the gene encoding 
the enzyme responsible for catalyzing the first step of formation of M6P (GlcNac-1-
phosphotranferase), causing the secretion of lysosomal hydrolases to the outside of the cell as 
these hydrolases do not get properly modified to be recognized by the M6PR transport 
machinery. Another such disease is the Niemann-Pick C (NPC) which results due defective 
cholesterol transporter (NPC1) activity (40, 46). 
There can be various proteins and lipids that can accumulate within the lysosomes in 
LSD, one of which is subunit c of mitochondrial ATP synthase which is seen in several LSDs 
(including Neuronal ceroid lipofuscinosis or NCL). Yeast cells that are deficient in btn1p 
(orthologue of CLN3) show altered vacuolar pH due to afflicted ATP synthase trafficking (47). It 
has been observed that usually LSD result in deficiency of enzyme(s) involved in the disease and 
cell compensates by upregulating the expression and synthesis of other lysosomal proteins. This 
is indicative of interdependence between the different lysosomal proteins (48). Studies 
elucidating the motif involved in the upregulation of lysosomal proteins during LSD point 
towards a ten base pair sequence close to the transcription start site called coordinated 
lysosomal expression and regulation (CLEAR). This element has been found in various lysosomal 
proteins such as CLN5, CLN3, LAMP-1, NPC1, NPC2 and β-galactosidase. Transcription factor EB 
(TFEB) binds to the CLEAR element and induces its transcription (48).  
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NEURONAL CEROID LIPOFUSCINOSIS (NCL) 
NCLs are a group of clinically and genetically heterogeneous progressive 
neurodegenerative disorders that mostly affect children. They are usually inherited in an 
autosomal recessive manner (49). The age of onset of NCLs is variable with varying symptoms 
such as epilepsy, mental and motor decline, visual loss and eventually premature death (49). 
NCLs result due to mutations in at least one of the 14 different genes that have been identified 
and associated with NCL (50). The incidence rate of NCLs is estimated to be 1:56,000 – 1:67,000 
(51) in the USA and 1:12,500 in the Scandinavian countries (52). The genes that are known to 
cause NCLs are – CLN1/ PPT1, CLN2/TPP1, CLN3, CLN4/DNAJC5, CLN5, CLN6, CLN7/MFSD8, 
CLN8, CLN9, and CLN10 (53). Although there have been extensive studies done on the NCL 
proteins, the function of most of them is still unresolved (54).  All NCL diseases have one factor 
in common; they all result in the accumulation of autofluorescent lipopigments within the 
lysosomes (50, 52, 55). Recently, a new nomenclature was proposed for the NCL diseases and 
the genes. This new nomenclature is according to the subtype of NCL followed by the age of 
onset of the subtype of NCL and electron microscopy (EM) findings (e.g., CLN3 disease, 
juvenile). To date there are 365 mutations known to cause NCL (53). The NCL genes are 
heterogeneous and consist of soluble lysosomal proteins (CLN1, CLN2, CLN5 and CLN10) as well 
as lysosomal transmembrane proteins (CLN3 and CLN7/MFSD) and some reside in the ER (CLN6 
and CLN8) (54). Although NCL proteins are ubiquitously expressed in different cells and tissues, 
neuronal cells are most affected by defective NCL proteins and the manifestations of the NCL 
disease are first observed in these cells (53). It has become imperative to develop model 
organisms to study these diseases. Over the last few years several model organisms have been 
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developed with NCL diseases available. There are vertebrate and invertebrate models of NCL 
disease. Vertebrate models include sheep, dog, cow and mouse 
(http://www.ucl.ac.uk/ncl/animal.shtml). Invertebrate models include yeast (S. cerevisiae and 
S. pombe), D. melanogaster and C. elegans (56). Table 1.1 summarizes the different NCL genes, 
the resulting phenotype and the defects caused by mutations in these genes.   
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Table 1.1- Summary of different NCL genes 
Gene Disease/ 
Subtypes 
Chromosomal 
location 
Intracellular 
localization 
Symptoms Storage 
material 
Function Mutations 
known 
Reference(s) 
CLN1/PPT1 Classic 
infantile, late 
infantile, 
juvenile and 
adult 
1p32 Lysosome 
(luminal) 
Motor skill 
deterioration, 
seizures, visual 
and speech 
failure 
SAP A and 
SAP D 
Fatty acid 
hydrolase 
61 (53, 57-64) 
CLN2/TPP1 Classic 
infantile, 
infantile, and 
juvenile  
11p15 Lysosome 
(luminal)  
Mental and 
speech failure, 
ataxia, loss of 
vision, 
epilepsy and 
myoclonic 
jerks 
Subunit c of 
mitochondrial 
ATP synthase 
Tripeptidyl 
peptidase 
89  
(53) (65-70) 
 
CLN3 Infantile, late 
infantile, 
juvenile,  and 
adult 
16p12.1 Lysosome 
(transmembrane) 
Hallucinations, 
visual 
deterioration, 
loss of motor 
coordination 
Subunit c of 
mitochondrial 
ATP synthase 
Unknown 59 (53, 71-78) 
 
CLN4/ 
DNAJC5 
Adult 20q13.33 Secretory 
vesicles in 
neurons 
Dementia, 
ataxia, seizures 
and myoclonus 
Sap A and D 
or  Subunit c 
of 
mitochondrial 
ATP synthase   
 Cysteine 
string 
protein 
alpha  
(CSP α) 
      - (79-83) 
CLN5 Infantile, late 
infantile 
variant, 
juvenile, and 
adult 
13q21.1-q32 Lysosome 
(luminal) 
Motor 
clumsiness, 
ataxia, loss of 
vision, 
seizures, 
mental 
retardation 
Subunit c of 
mitochondrial 
ATP synthase 
Unknown 33 (53)  
(84-92) 
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Gene Disease/ 
Subtypes 
Chromosomal 
 location 
Intracellular 
localization 
Symptoms Storage 
material 
Function Mutations 
known 
Reference(s) 
CLN6 Late 
infantile 
and Adult 
15q21-q23 ER 
(Transmembrane) 
Motor 
difficulties, 
seizures, ataxia, 
mental 
retardation, loss 
of vision 
Subunit c of 
mitochondrial 
ATP synthase 
Unknown 63 (65, 93)) 
(53) (93-96) 
 
CLN7/ 
MFSD8 
Late 
infantile 
variant 
and 
Juvenile 
4q28.1-q28.2 Lysosome 
(transmembrane) 
Developmental 
decadence, 
seizures, ataxia, 
vision failure, 
ambulatory 
problems 
         - Lysosomal 
transporter 
31 (53) 
(97-100) 
CLN8 Variant 
late 
infantile 
and 
EPMR 
8p23 ER 
(Transmembrane) 
Ataxia, speech 
delay, 
myoclonus, loss 
of vision, 
seizures and 
mental decline 
Subunit c of 
mitochondrial 
ATP synthase 
Unknown 25 (53)(101-
106) 
 
CLN10/ 
CTSD 
Congenital 11p15.5 Lysosome 
(luminal) 
Post natal 
respiratory 
insufficiency 
and status 
epilepticus 
        - Aspartyl 
protease 
4 (53) (107-
110) 
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CLN5 
This thesis work focuses mainly on CLN5 protein and the role of N-glycosylation in the 
trafficking of CLN5 to the lysosome. Thus it is imperative to discuss CLN5 in more detail. The 
CLN5 disease has different forms – infantile, late infantile, juvenile and adult. It is also known as 
variable late infantile (vLINCL). The disease onset is usually between 4-7 years of age and the 
main symptom observed is motor clumsiness (84, 85) along with epileptic seizures, ataxia, 
mental and visual deterioration (84, 86, 87). Children usually go blind by the age of 7-10 and 
death occurs between the ages of 10-30 years (86, 95). Brain studies have shown cerebellar 
atrophy to be a notable characteristic of CLN5 disease (86). In CLN5 disease, late infantile and 
juvenile are associated with Fingerprint (FP) morphology of storage granules occasionally mixed 
with Curvilinear bodies (CL) or rectilinear bodies (RL) (94, 111). FP and granular osmiophilic 
deposits (GROD) lipopigments morphology are observed in the adult and infantile subtype of 
CLN5 (51, 112). Subunit c of mitochondrial ATP synthase is the main storage material that is 
seen to accumulate in lysosomes (88). 
CLN5 maps to chromosome 13q21.1-q32 and consists of 407 amino acids (89-91). CLN5 
is heavily glycosylated with a reported molecular weight of ~ 60 kDa (90, 113). One of the 
unusual characteristic of CLN5 protein is that it possesses a long signal peptide sequence (96 
aa) (89). CLN5 does not share any homology with any other protein(s) and its function remains 
to be elucidated (90, 91). There has been speculation of the intracellular localization of CLN5 
but it is generally accepted to be a soluble lysosomal glycoprotein (89, 90, 114). Lysosomal 
targeting of CLN5 follows M6PR pathway, although M6PR independent pathways have also 
been shown to be utilized by CLN5 to reach the lysosomes (81, 89, 115). 
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To date, there are 33 mutations known for CLN5 gene (53). All the missense mutations 
studied so far (p.R112H, p.R112P, p.D279N, and p.W379C) cause retention of CLN5 in ER 
possibly due to misfolding or defect in trafficking (89, 116). Although CLN5 mutations were 
initially reported mainly in Finnish populations, it is now clear that CLN5 mutations have a 
worldwide distribution with mutations reported in over 15 different countries (51). Even 
though the function of CLN5 is not known, it has been reported to interact with PPT1/CLN1, 
CLN6 and CLN8 in ER (117) and with TPP1/CLN2 and CLN3 in the lysosomes (118). It has also 
been implicated to play a role in lysosomal receptor recycling via the recruitment of retromer 
(113). 
 Mutations in the N-glycosylation sites have been known to have a drastic effect on other 
NCL proteins (CLN1 and CLN2) by affecting their activity and/or localization. CLN2/TPP1 has five 
N-glycosylation sites of which one of them (Asn286) has been shown to be important for 
targeting to the lysosome (119). The role of N-glycosylation in proper trafficking of CLN5 to the 
lysosome has not been studied. Such a study is interesting as CLN5 has eight potential N-
glycosylation sites and to elucidate which ones are important will be essential in characterizing 
it. 
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ABSTRACT 
 
CLN5 is a soluble lysosomal protein with unknown function.  Mutations in CLN5 lead to 
neuronal-ceroid lipofuscinosis (NCL), a group of inherited neurodegenerative lysosomal storage 
disorders that mainly affect children. NCLs have distinct clinical symptoms that include mental 
retardation, loss of vision, epilepsy, and impediment of motor capabilities. Buildup of 
autofluorescent lipopigments called lipofuscin in the lysosome is observed with subunit c of 
mitochondrial ATP synthase being the main storage material. CLN5 is a heavily glycosylated 
protein with eight potential N-glycosylation sites based on the Asn-X-Ser/Thr consensus 
sequence. It has been shown to utilize the mannose 6-phosphate (M6P) pathway to reach the 
lysosomes. By mutating asparagine to glutamine in the N-glycosylation consensus sequences, 
we showed that all eight putative N-glycosylation sites are used in vivo.  From localization 
studies, we found that certain N-glycosylation sites are important for protein folding and 
trafficking as mutating these sites (N179Q, N252Q, N304Q, and N320Q) lead to the retention of 
CLN5 in the ER.  One particular site, N401, is essential for trafficking out from the Golgi, as CLN5 
with N401Q mutation mislocalized to the Golgi. We also analyzed several known patient 
mutations that result in the mislocalization of CLN5 similar to the N-glycosylation mutants. 
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INTRODUCTION 
The Neuronal ceroid lipofuscinosis (NCLs), also known as Batten disease, are a group of 
progressive neurodegenerative disorders mainly affecting children.  The NCLs are characterized 
by mental retardation, impediment of motor capabilities, loss of vision, epileptic seizures, and 
eventually causing death.  Depending on the onset, progression and the neurological 
symptoms, there are several forms of NCL that have been identified as infantile (INCL), late 
infantile (LINCL), juvenile (JNCL) and adult (ANCL) (1). The incidence of this disease is 1:100,000 
worldwide (2) but it is more common in the USA where the incidence rate is between 1:56,000 
to 1:67,000 (3) and even higher in Scandinavian countries with the incidence rate being 
1:12,500 (2). There are at least fourteen different established disorders falling under NCL (4) 
but the exact function of most of these genes (CLN1-CLN14) is not well established (1).  NCL is 
classified as a lysosomal storage disorder based on the buildup of autofluorescent lipopigments 
called lipofuscin in lysosomes of neurons as well as other cell types (2, 5, 6).  The main storage 
material usually seen accumulated is the subunit c of mitochondrial ATP synthase (7) and 
Saposin A and D (8). In mouse models of NCL disease some secondary lipids such as 
glycosphingolipids, dolichol, bis (monoacylglycero) phosphate or cholesterol have also been 
reported to accumulate (9). Although NCL proteins are ubiquitously expressed, neuronal cells 
are most affected by dysfunctional NCL proteins (10).  
CLN5 mutations were initially reported to be limited to Finnish and other Northern 
European populations, but recently it has been reported to be present in Columbian, 
Portuguese, Pakistani, Afghan and Italian population, making the disease’s ethnic distribution 
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more diverse (3).  The exact function of this protein is not known and it does not share 
homology with any other protein(s) (11, 12).  CLN5 protein consists of 407 amino acids with a 
signal sequence of ~96 amino acids.  Although in silico analysis suggests it has a transmembrane 
domain (11, 12), it has been shown to be a soluble protein (13)  and is reported to localize to 
the endosomal-lysosomal compartment (13, 14).  Transient over-expression of CLN5 
demonstrated that the protein has a molecular weight of ~60 kDa and is heavily glycosylated 
(14, 15). Stable expression of CLN5 in a SH-SY5Y neuronal cell line showed that CLN5 can be 
detected as a 60 kDa proform and 50 kDa mature form before reaching the lysosomes (16).  
Although not much is known about CLN5, it has been reported to interact with other NCL 
proteins – CLN2 and CLN3 (12) as well as CLN1/PPT1, CLN6, and CLN8 (17). Interaction of CLN5 
with CLN2 is reported to take place in the late endocytic compartment and it has been 
suggested that CLN5 may be a connecting link between the different NCL proteins (17). A 
recent study reported CLN5 to be integral for the recruitment of retromer, which in turn was 
responsible for the sorting and recycling of lysosomal receptors (15) .  
Post-translational modifications play an important role in the maturation, folding and 
trafficking of many proteins. One of the main modifications proteins undergo during and after 
translation is glycosylation. N-glycosylation is the addition of oligosaccharides onto an 
asparagine (Asn) residue. The addition of oligosaccharide chain to Asn is not random and 
usually follows a consensus sequence of N-X-S/T where X is any amino acid apart from proline. 
The addition of core sugar structure takes place in the ER and further modifications to the sugar 
(trimming or additions) take place in the Golgi (e.g., phosphorylation of mannose) (18-20). One 
of the best characterized role of N-glycosylation is the targeting of acid hydrolases to the 
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lysosomes. The Mannose-6-phosphate (Man-6-P) residue on the acid hydrolases is recognized 
by mannose 6-phosphate receptors (M6PR) in the trans-Golgi network which carry their cargo 
to the late endosomes/lysosomes.  
CLN5 is a highly glycosylated protein with almost 40% of its molecular weight attributed to 
glycosylation. This has been demonstrated by the digestion of CLN5 with Endo H (cleaves 
mostly high mannose sugars), PNGase F (cleaves N-linked glycosylation) and also by 
tunicamycin treatment (prevents N-glycosylation) (14, 16) which results in the reduction of size 
of the protein from ~60 kDa to ~35 kDa. Based on the consensus sequence N-X-S/T, CLN5 has 
eight potential N-glycosylation sites at Asn179, 192, 227, 252, 304, 320, 330, and 401 (12, 14). 
Proteins that are destined to the lysosome normally contain one or more M6P residues on their 
N-linked oligosaccharides, which are recognized by M6PR and escorted to the lysosomes. Mass 
spectrometry analysis has predicted that human CLN5 potentially contains three such M6P sites 
at Asn 320, 330, and 401 (21). M6PR bind to M6P residues and transport the cargo protein to 
the endosome, where the M6PR detach from their cargo due to the acidic environment and are 
recycled to the (TGN) and are ready to bind cargo again (20). The CLN5 protein is then able to 
reach the lysosome from the endosome. Even though CLN5 has been predicted to contain three 
M6P residues, it has been reported that CLN5 is capable of utilizing M6PR independent 
pathway(s) in addition to the classical M6PR pathway to reach the lysosomes (16). Tripeptidyl-
peptidase I (TPPI) is a good example of a lysosomal enzyme which is targeted to the lysosomes 
via the MPR dependent pathway (18, 22). It has five N-glycosylation sites, of which one of them 
(Asn286) has been shown to be the most important for the transport and activity of TPPI (18).  
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 Here we studied the role of N-glycosylation on the trafficking of CLN5 protein. We utilize 
site directed mutagenesis to create mutants for each of the eight predicted N-glycosylation 
sites and look at the change in size and localization of each of these mutants using western 
blotting and immunofluorescence. We show that all the eight potential N-glycosylation sites are 
used in vivo and that the loss of N-glycosylation at certain sites leads to CLN5 being mislocalized 
either to the ER or the Golgi, whereas other mutants do not mislocalize and are able to reach 
the lysosome. This study sheds light on the importance of N-glycosylation on the transport of 
human CLN5 protein. The progress in understanding CLN5 has been hindered since not much is 
known about this protein. Here we show importance of some of the basic modifications (N-
glycosylation) on CLN5 and how changing these modifications have a drastic effect on the 
localization of CLN5. 
 
MATERIALS AND METHODS 
Reagents 
Cell culture media and reagents were purchased from Hyclone.  Chemiluminescent HRP 
substrate kit was purchased from Millipore. Endoglycosidase H (Endo Hf), peptide-N-glycosidase 
F (PNGase F), O-glycosidase, T4 Polynucleotide kinase (PNK), Quick ligase, colorplus protein 
marker and restriction enzymes were from New England Biolabs (NEB). The TransIT-LT1 
transfection reagent was from Mirus life technologies. The phusion PCR kit and chemically 
competent DH5-α E.coli cells were from NEB. Cycloheximide and 37% paraformaldehyde was 
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purchased from Fisher scientific. Tunicamycin was from Enzo life sciences. Rab5 mutant plasmid 
eGFP-Rab5A Q79L was purchased from Addgene ( Addgene plasmid 28046) (23). 
 
Antibodies 
 Mouse monoclonal antibody (α-Myc) producing hybridoma cell line 9E10 was purchased from 
ATCC (CRL 1729). Rabbit polyclonal antibodies used in this study were Calnexin for ER 
(Genscript), Grasp65 for Golgi (Affinity bioreagents), Lamp1, Lamp2 for Lysosomes, EEA1 for 
early Endosomes, and  goat anti VPS35/MEM-3 for Retromer (all from Pierce). HRP-conjugated 
secondary antibodies for western blotting were purchased from Jackson laboratories. 
Secondary antibodies conjugated to Alexa Flour 488, 546, 647, and 633 were from Molecular 
probes. Rabbit α-CLN5 Ab (IRmII-4) was kindly provided by Dr. Kyttala (13). Mouse α-Lamp1 
(H4A3) was purchased from the Developmental Studies Hybridoma Bank (Iowa City, IA). 
 
Site-directed mutagenesis 
The cDNA encoding wild type CLN5 (Purchased from Gene Copoeia, MGC: 184226) was cloned 
into pcDNA3.1/myc-His(-)A between EcoRI and BamHI restriction sites.  This was used as the 
template for preparing individual N-glycosylation mutants by changing the codon for Asn to Gln 
within the consensus sequence for N-glycosylation Asn-X-Ser/Thr. Mutated cDNAs were 
generated using phusion site-directed mutagenesis kit. cDNAs containing single mutation for 
the N-glycosylation sites served as templates for creating multiple N-glycosylation mutants. In 
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these multiple mutants also, the codon for Asn was replaced with Gln. The mutations were 
confirmed by sequence analysis. The primer sequences used to generate different N-
glycosylation mutants are shown in table 2.1. 
 
Cell culture and transfections  
Cells were grown and maintained in Dulbecco’s modified eagle medium (HeLa cells ATCC CCL-2) 
supplemented with 10% fetal bovine serum (FBS), glutamax, HEPES and gentamycin at 37o C in 
a humidified incubator with 5% CO2. 24 h before transfection, the cells were seeded on a 6-well 
culture plate at ~30% confluency.  Cells were transiently transfected using Mirus Trans IT-LT1 
transfection reagent according to manufacturer’s recommendation. 24 h after transfection cells 
were collected and the cell pellet was either used immediately for western blotting or stored at 
-80o C until use. 
 
SDS-PAGE and western blotting 
Cells were lysed using RIPA lysis buffer (50 mM Tris pH 8, 150 mM NaCl, 1% NP40, 0.1% SDS, 
0.5% sodium deoxycholate and protease inhibitor mix) on ice for 30 min. The clear lysate was 
collected after spinning at 13000 rpm for 5 min and sample buffer was added. For media 
samples, a 60% ammonium sulfate precipitation was carried out to precipitate proteins from 
serum free media. The samples were boiled for 5 min and loaded onto 10% SDS-PAGE. The 
electrophoretically separated proteins were then transferred onto a PVDF membrane. The 
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membrane was blocked with 5% milk in TBST (20 mM Tris-HCl pH 7.4, 150 mM NaCl and 0.05% 
Tween20) and incubated with primary antibody for 1.5 h at room temperature or overnight at 
4o C. The membrane was then washed with TBST and incubated with the peroxidase-
conjugated secondary antibody diluted to 1:50,000 in TBST for 45 min at room temperature and 
developed using Chemiluminescent HRP substrate. The membrane was imaged using G box 
imager from Syngene. 
 
Immunofluorescence microscopy 
Cells were grown on circular glass coverslips and transiently transfected as described before. 
The cells were treated with cycloheximide (50 µg/ ml) for 2 h before fixing with 4% 
formaldehyde for 10 min at room temperature or 100% methanol at -20o C for 20 min. Blocking, 
permeablization, antibody incubations and washing were done using blocking solution (10% 
fetal calf serum, 0.1%saponin and 0.02% sodium azide in PBS). The primary antibody was 
diluted in the blocking solution and incubated for 1 h at room temperature. The coverslips were 
washed 3-4 times with the blocking solution and the secondary antibody conjugated to 
fluorochromes was also diluted in the blocking solution and incubated at room temperature for 
1 h in the dark. The coverslips were washed and mounted onto glass slides with mounting 
media and stored at in dark at 4o C until imaging. The cells were imaged using a Zeiss LSM-5 
PASCAL laser scanning confocal microscope. 
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Deglycosylation experiments 
Cells were lysed using native lysis buffer (25 mM Tris-HCl pH 8, 300 mM NaCl, 1% triton X-100 
and protease inhibitor mix) for 30 min on ice and spun down at 13,000 rpm for 5 min. The 
cleared lysate was used for deglycosylation experiments. Deglycosylation of samples was 
performed using peptide N-glycosidase F (PNGase F) and endoglycosidase H (Endo H) according 
to manufacturer’s recommendation. For tunicamycin (1 µg/ml) treatment, it was added to cells 
at the time of transfection. Digestion with the enzymes was carried out according to the 
manufacturer’s protocol for 3 h at 37o C. The digest was then run on SDS-PAGE followed by 
western blotting as described before.  
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Table 2.1 List of primer sequences 
Mutation Forward primer sequence Reverse primer sequence 
N179Q 5’- ACTGGCAAGCAGTACACAATGGAA-3’ 5’-TAATGTCGTCCTGAATCCAATGGCATC-3’ 
N192Q 5’- CAACTTGGCCAGTGTACATTTCCCCATCTCCGACC-3’ 5’- GAAAAGTTCATACCATTCCATTGTGTAGTTCTTGCC-3’ 
N227Q 5’- TGGAAGGAACAGGGGACATTAGTTCAAGTAGCAAC-3’ 5’-GTGAACATCATCAATTCCCTCAAAAAAGCAGGCAGCGCC-3’ 
N252Q 5’- TGGGTGAAACAGGACCAGGAAACAGGAATTTATTATGAG-3’ 5’-CTTTGCCATTTGGTTGAACATGTTTCC-3’ 
N304Q 5’-ATAGAAACCCAGTATACAAGAATATTTCTTTACAGTGG-3’ 5’-GTTCTTGAACTCTGATCCAAATTCAGCCAACTTG-3’ 
N320Q 5’-TACCTGGGACAGGAAACATCTGTTTTTGGGCC-3’ 5’-GGTAGGTTCTCCACTGTAAAGAAATATTC-3’ 
N330Q 5’-CCAACAGGACAGAAGACTCTTGGTTTAGCC-3’ 5’-CCCAAAAACAGATGTTTCATTTCCCAG-3’ 
N401Q 5’-CCTATCAGACAGAAAACACTCTCTGGT-3’ 5’-TAAAGGGATTTCTTCATATGTTATTTT-3’ 
D279N 5’-GATTCCTACAACTGTTCCAAATTTGTGTTAAGGACC-3’ 5’-AAACCATGTCTCTGCCCCCTTTTCTGGGCTGGC-3’ 
N192S 5’-CAACTTGGCAGCTGTACATTTCCCCATCTC-3’ 5’- GAAAAGTTCATACCATTCCATTGTGTAGTTCTTGCC -3’ 
Y392X 5’-GGATCCGAGCTCGGTACCAAGC-3’ 5’-TGTTATTTTAATAAAAGGGAATTTCATAGG-3’ 
Underlined bases indicate changed amino acid codon.
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RESULTS 
N-glycosylation of CLN5 in vivo 
The Human CLN5 protein consists of 407 amino acids with eight putative N-glycosylation 
sites located at Asn 179, 192, 227, 252, 304, 320, 330 and 401.  To determine which of these 
eight N-glycosylation sites is/are utilized in vivo, we removed each of these potential sites in 
CLN5 cDNA by substituting Asn codon with Gln codon within the consensus sequence N-X-S/T.  
The CLN5 cDNA with single N-glycosylation sites mutated (N179Q, N192Q, N227Q, N252Q, 
N304Q, N320Q, N330Q and N401Q) was used for transient expression in HeLa cells.  We also 
created a mutant with an additional N-glycosylation site at Asp 279 (D279N), which is the same 
as a patient mutation seen mainly in the European population (12).  The wild type CLN5 
migrated on gel as a species of molecular weight of ~55 kDa.  All eight N-glycosylation mutants 
showed a mobility shift corresponding to ~2.5 kDa reduction in size compared to wild type, 
indicating all eight putative N-glycosylation sites are indeed utilized in vivo  (Fig. 2.1 A).  The 
D279N mutant, as observed by others, migrated ~2.5 kDa higher than wild type CLN5.   
To confirm that the reduction in size of mutants was due to the abrogation of N-
glycosylation sites and not because of changing the amino acid to Gln, we changed Asn192 to 
Ser (N192S). The N192S mutant, which is also a patient mutation (10), showed similar reduction 
in size as the other single mutants (Fig. 2.1 B).  Thus, these findings confirmed that all the eight 
potential N-glycosylation sites in CLN5 are used in vivo and removing them results in a 
reduction of ~2.5 kDa in the single mutant.  We then created a double mutant with two of the 
N-glycosylation sites of CLN5 mutated (N192Q + N330Q). The double mutant ran ~2.5 kDa 
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lower than the single mutant and ~5 kDa lower than wild type CLN5 (Fig. 2.1 C), indicating that 
the reduction in size was due to the removal of two N-glycosylation sites.  
 
Subcellular localization of CLN5 N-glycosylation mutants 
 CLN5 has been reported to be a lysosomal luminal protein and has been shown to reach 
the lysosomes via mannose-6 phosphate dependent and independent pathways (16).  
Glycosylation is important for proper folding and/or trafficking of luminal and secreted 
proteins.  To assess the role of N-glycosylation in CLN5 localization, we examined subcellular 
localization of the N-glycosylation mutants.  After 2 h of cycloheximide (CHX) chase (50 µg/ml), 
HeLa cells expressing CLN5 wt and mutants were fixed and immunostained for CLN5 with α-
Myc antibody.  Confocal microscopy analysis showed that the N192Q and N227Q mutants 
colocalized partially with the lysosomal marker Lamp2, similarly to CLN5 wt (Fig. 2.2 A and B).  
In our system, we have only been able to partially colocalize CLN5 with lysosomal markers.  To 
address this issue, we used rabbit antiserum against CLN5 (IRmII-4) (13) to label for transiently-
expressed CLN5 along with mouse antibody against Lamp1.  CLN5 clearly colocalized with 
Lamp1 (Fig. S1), albeit the rabbit antiserum stained with higher cellular background compared 
to the mouse α-Myc antibody.  N179Q, N252Q, N304Q and N320Q did not colocalize with 
lysosomal markerLamp2 (data not shown), but instead colocalized with ER marker Calnexin (Fig. 
2.2 D).  N330Q, on the other hand, was observed in the ER as well as in lysosomes (Fig. 2.2 E).  
The N401Q mutant colocalized with the Golgi marker Grasp65 (Fig. 2.2 C).  These findings 
suggest that some of the N-glycosylation sites (N179, 252, 304, 320 and 330) are crucial for the 
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folding of CLN5, as obliterating these N-glycosylation sites results in CLN5 protein being 
retained in the ER, although N330Q had a milder phenotype. N401 appears to be essential for 
trafficking from the Golgi to the endosome/lysosomes, whereas N192 and N227 seem to have 
lesser roles in the folding or trafficking of CLN5.  
 To further assess the localization of wild type CLN5 as well as mutants that partially 
localized to the lysosome from above (N192Q, N227Q and N330Q), we decided to co-express 
these N-glycosylation mutants along with a mutant for Rab5 (eGFP-Rab5A Q79L). The small 
GTPase Rab5 gives the identity to early endosomes and has been used as an early endosome 
marker.  The mutant Rab5A Q79L has a defective GTPase activity, resulting in the fusion and 
formation of enlarged endosomes (23, 24). Therefore, proteins destined to reach the lysosomes 
accumulate within the enlarged endosomes (luminal proteins) or on the limiting membrane of 
the enlarged endosomes (transmembrane proteins).  HeLa cells were co-transfected for 24 h 
with eGFP-Rab5A Q79L and N-glycosylation mutants followed by 2 h of CHX chase before 
fixation.  The lysosomal mutants (N192Q and N227Q) and wild type CLN5 localized to the inside 
of enlarged endosomes (Fig. 2.3 A), indicating that they truly localize to the 
endosome/lysosome. The ER mutants (N179Q, N252Q, N304Q and N320Q) were not detected 
inside the enlarged endosomes, but instead they were observed outside the enlarged 
endosomes (Fig 2.3 C).  The mutant N401Q colocalized with Golgi marker (Grasp65) very well 
and did not localize inside the enlarged endosomes (Fig. 2.3 B).  The N330Q was seen to localize 
equally to either inside or outside the enlarged endosomes (Fig. 2.3 D).  These results 
conclusively show that N192Q and N227Q mutants can reach the endosome/lysosome, as does 
wild type CLN5.  However, majority of the other mutants are either retained in the ER (N179Q, 
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N252Q, N304Q, N320Q) or cannot move forward beyond the trans-Golgi network (N401Q).  We 
noted that small populations of all mutants escaped from the ER and were seen in the enlarged 
endosomes. 
 Based on the immunofluorescence imaging data, we categorized the N-glycosylation 
mutants depending on their localization. Table 2.2 summarizes the imaging data according to 
the colocalization with Lamp2, Calnexin, Grasp65 and whether the N-glycosylation mutant CLN5 
localizes inside or outside of the enlarged endosomes of the mutant eGFP-Rab5A Q79L. Thus 
the N-glycosylation mutants can be categorized based on their subcellular localization as either 
lysosomal, ER or Golgi. 
 
Deglycosylation studies of CLN5 
 It has been reported that CLN5 is Endoglycosidase H (Endo H) sensitive (14) and digestion with 
Endo H results in a reduction of the CLN5 molecular weight.  After Endo H treatment, all the 
single mutants (including D279N) and wild type CLN5 had the same gel mobility of ~35 kDa (Fig. 
2.4 A).  This further confirmed that the 2.5 kDa size difference in mutants was due to removal of 
N-glycosylation, because removal of oligosaccharide chains eliminated the size difference 
between wild type and the mutants. This also implicates that all N-glycans on CLN5 are Endo H 
sensitive, as Endo H digestion on the mutants did not reveal any resistant chains (Fig. 2.4 A). If 
there were any Endo H resistant chains, then N-glycosylation mutant(s) of that site(s) would 
have had a lower gel mobility compared to CLN5 wt band. Complex and some hybrid sugars are 
resistant to Endo H digestion, suggesting that the CLN5 N-glycosylation sites mostly consist of 
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high mannose type sugars. The difference in the size of wild type CLN5 and Endo H digested 
CLN5 was ~20 kDa (Fig. 2.1 A and 2.4 A), which can be explained by eight oligosaccharide chains 
of ~2.5 kDa each observed in CLN5.  
To investigate N-glycosylation modification further, we digested CLN5 with peptide N-
glycosidase F (PNGase F).  Endo H cuts after the first N-acetyl glucosamine of the 
oligosaccharide chain on the Asn, thus leaving one sugar moiety (GlcNAc) on Asn.  In contrast, 
PNGase F cuts immediately after the Asn and does not leave any sugar moiety.  When we 
treated wild type CLN5 with PNGase F, we observed faster migration of CLN5 compared to Endo 
H treatment, consistent with eight N-acetyl glucosamine moieties being further removed (Fig. 
2.4 B).  We also examined the effect of tunicamycin treatment (1 µg/ml) on CLN5 expression.  
Tunicamycin prevents the first step of N-glycosylation in the ER, thus preventing any N-
glycosylation from taking place.  Interestingly, we observed a faster migration of tunicamycin 
treated CLN5 wt (~32 kDa) compared to PNGase F treated CLN5 wt (Fig 2.4 B).  This result 
indicates that there is/are other modification(s) on CLN5 beyond the N-glycosylation. It should 
be noted that we cannot rule out the possibility of the size difference being due to PNGase F 
digestion converting the Asparagine to Aspartic acid on each N-glycosylation site. 
Since tunicamycin treatment caused CLN5 being retained in the ER (data not shown), any 
modification beyond the ER would not occur.  To test if this extra modification happens after 
CLN5 exits the ER, we used N-glycosylation mutants that primarily localized to the ER so as to 
examine their modification. Surprisingly, when we digested N320Q with PNGase F, we observed 
faster mobility shift compared to other ER mutants and CLN5 wt (Fig. 2.4 C), although 
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tunicamycin treated sample still ran lower than N320Q.  This indicates that there is a possibility 
of a PNGase F resistant residue being present on Asn320 which is abolished in the N320Q 
mutant resulting in the migration difference, although a PNGase F resistant linkage is rare in 
animals and common in plants. These experiments show that there are potentially other 
modifications apart from N-glycosylation that could be taking place on CLN5 and that these 
modifications possibly take place post ER or post N-glycosylation. 
Stability of CLN5 deficient in N-glycosylation 
  In immunofluorescence studies, we noted that the lysosomal mutants had lower CLN5 
signal than ER and Golgi mutants after 2 h of CHX chase. To investigate if the lysosomal mutants 
were being degraded or turned over more efficiently than the other mutants, transient 
transfection of HeLa cells was performed for 24 h followed by CHX chase for 0, 2 and 4 h.  Since 
we and others have previously detected CLN5 in media (secreted out), we changed media at 
time of CHX chase and collected media at 2 and 4 h to examine if lower protein levels 
correspond to an increase in secreted CLN5.  The lysosomal mutant protein levels gradually 
decreased in the pellet with increasing time of CHX chase and this corresponded to the increase 
in CLN5 being detected in the media with increasing time of CHX treatment (Fig. 2.5).  Among 
the ER mutants, N179Q, N252Q, and N330Q showed stable protein levels in the pellets at all 
time points without any protein being detected in the media. While N304Q, N320Q, and D279N 
patient mutant showed some degree of reduced protein level in the pellet, interestingly, for 
N401Q the decreasing levels in the pellets and the increasing levels in the media were more 
dramatic than the lysosomal mutants (N192Q and N227Q) and CLN5 wt. These results show 
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that N-glycosylation has varied effect on the stability of CLN5, indicating that some of the N-
glycosylation sites are essential for the proper folding and stability of CLN5 and depleting those 
sites results in CLN5 being degraded. 
 
Subcellular localization of CLN5 patient mutations 
  Since N192Q mutant localizes to the lysosome just like wild type CLN5 does, we decided to 
examine the localization of patient mutation N192S.  Compared to other patient mutations 
D279N and Y392X that localized to the ER, the N192S was observed in the enlarged endosomes 
in cells expressing eGFP-Rab5A Q79L (Fig. 2.6).  This suggests that, unlike D279N and Y392X that 
cannot fold properly and therefore are retained in the ER, the N192S mutant has functional 
defect in the lysosome.  This was the first patient mutation that was characterized and shown 
to localize to the lysosome. The D279N mutant localized outside of the enlarged endosomes 
and also with ER marker Calnexin (Fig. 2.6).  Y392X mutant did not localize to inside of enlarged 
endosomes nor with Golgi marker Grasp65 (Fig. 2.6). 
 
DISCUSSION 
 While the function of CLN5 is not known at the moment, it is clear that several 
modifications occur during or after translation which might have an effect on its function, 
stability and trafficking.  Based on experimental evidence and sequence prediction, it is clear 
that the N-terminus undergoes signal peptide cleavage in the ER during co-translation (16).  
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From the available sequences, it is apparent that signal peptide of CLN5 in primate is unusually 
long (see alignment in supplementary figure S2) compared to other species.  Another major 
modification is N-glycosylation.  In this report, we demonstrate that all eight putative N-
glycosylation sites of human CLN5 are utilized in vivo.  Seven of the eight N-glycosylation sites 
are conserved among mammalian species (supplementary Fig. S2).  In Mus musculus and Rattus 
norvegicus, the N-glycosylation site corresponding to human N401 is not present.  We have 
uncovered that N401 is essential for lysosomal trafficking of human CLN5, as N401Q 
predominantly localized to the Golgi after 2 hour CHX chase (Fig. 2.2 C and 2.3 B) and majority 
of N401Q CLN5 was secreted out to the media (Fig. 2.5).  Interestingly, mouse CLN5 has been 
shown to reach lysosomes in M6PR independent manner (16).  Asparagines on residue 401, 
320, and 330 of human CLN5 were predicted to have a M6P tag attached in a proteomic scaled 
mass spectrometry analysis (21).  However, from our results we know that N330Q can reach 
beyond the endosome (Fig. 2.2 E and 2.3 D), indicating that this residue may not be involved in 
M6PR-mediated transport.  The N-glycosylation on N320 is essential for proper folding, as 
N320Q was retained in the ER (Fig. 2.2 D and 2.3 C).  Therefore we cannot evaluate its 
involvement in TGN to endosome trafficking.  N401, on the other hand, has a clear role in 
transport from Golgi to the endosome as N401Q mutant was either retained in the Golgi (Fig. 
2.2 C and 2.3 B) or secreted out of the cell (Fig. 2.5), similar to the effect of I-cell disease where 
loss of M6P tag leads to most lysosomal acid hydrolases being secreted out of the cell.  N-
glycosylation on residue 401 also confirms that CLN5 is not a transmembrane protein as some 
prediction program suggested, because a single transmembrane domain at region 352-373 
would position N401 at the cytoplasmic side. 
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 CLN5 has been reported to localize to the lysosome (13, 14).  However, in our system, we 
can only partially co-localize CLN5 with lysosomal markers.  In attempt to address this issue, we 
used rabbit antiserum against CLN5 (IRmII-4) (13) to label overexpressed CLN5 (this antiserum, 
as well as other CLN5 antibodies, do not recognize endogenous CLN5).  There were punctate 
structures labeled with CLN5 that clearly colocalized with lamp1 (Fig. S1).  CLN5 also partially 
colocalizes with endosome markers EEA1 and retromer (data not shown).  With eGFP-Rab5A 
Q79L co-expression, we have shown CLN5 to localize to the inside of enlarged endosomes, 
verifying its presence in the endosome/lysosome pathway(s).  A recent study indicated a role of 
CLN5 in regulating retromer recruitment to the endosomes (15).  When CLN5 was depleted, the 
cellular levels of endosomal/lysosomal cargo receptors: cation-independent M6PR (CI-M6PR) 
and sortilin were reduced.  Our colocalization data is consistent with a function of CLN5 in the 
endosomes. 
 Using Endo H glycosidase, we showed that all eight N-glycans are Endo H sensitive, because 
by deleting individual N-glycosylation, we did not observe lower molecular weight product 
when mutant CLN5 was treated with Endo H. This can be explained by the fact that if there is an 
Endo H resistant N-glycan and when that specific N-glycosylation site is removed, we should 
observe a lower molecular weight product compared to wild type CLN5 upon Endo H digestion.  
However, with Endo H digestion, all mutants and wild type CLN5 ran the same without any 
mobility shift.  Intriguingly, a PNGase F resistant N-glycan was identified on N320, as digestion 
with PNGase F of N320Q mutant resulted in a lower molecular weight species.  PNGase F 
cannot digest the core N-acetyl-glucosamine that is modified by an α 1-3 fucose.  However this 
modification is rare in animal cells.  Another interesting finding is that with tunicamycin 
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treatment, we observed an even lower molecular weight CLN5.  Tunicamycin inhibits the 
enzyme GlcNAc phosphotransferase and therefore prevents N-glycosylation.  In tunicamycin-
treated cells, CLN5 localizes to the ER (data not shown).  It is possible that due to retention in 
the ER, CLN5 is not accessible to other modifications that occur past the ER which would be 
consistent with tunicamycin treated CLN5 wt running lower that PNGase F treated CLN5 wt. 
 Previous characterized patient mutations with aberrant N-glycosylation include D279N, 
N192S, and Y392X.  We show that D279N mutation introduces an extra N-glycosylation site to 
CLN5 which causes an increase in its molecular weight (Fig. 2.1 A).  This causes CLN5 to be 
retained in the ER (Fig 2.6).  Y392X has been reported to localize to the ER as well as the Golgi 
(12).  Since this slightly truncated version of CLN5 does not have the N401 residue, it’s possible 
that its main defect is the missing N-glycan on N401 residue and it would behave similar to the 
N401Q mutant.  However we observed ER retention of the Y392X mutant (Fig. 2.6), indicating 
that missing the last 15 amino acids of CLN5 has a more dramatic effect on the overall folding 
compared to the N401Q mutant.  In this report we also characterized the localization of a 
patient mutation N192S.  Similar to N192Q N-glycosylation mutant, we observed normal 
lysosomal/endosomal localization of N192S (Fig. 2.6).  This suggests that N192S is a mutant with 
defect in its lysosomal function, rather than general folding issues as seen with other patient 
mutations of CLN5.  This opens up new avenues to explore the function and role of CLN5 in the 
lysosome using N192S mutant as a tool for these studies. 
 This study explores the role of N-glycosylation and its importance in the stability and 
transport of CLN5 protein. It aids the field of NCL and CLN5 to move forward by characterizing 
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some of the basic facets of human CLN5 protein. Although the function of CLN5 is not known, it 
is possible that N-glycosylation plays a major role in the proper functioning of CLN5 in the 
lysosomes, similar to TPP1 (18). 
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Figure 2.1- N-glycosylation of CLN5 in vivo. (A) Western blot analysis of CLN5 wt and N-
glycosylation mutants. HeLa cells were transiently transfected for 24 h and the whole cell lysate 
(WCL) was collected used for western blotting analysis using mouse α-Myc antibody to detect 
CLN5. Equal amount of protein was loaded onto each well. (B) Western for confirming mobility 
shift is due to abrogation of the N-glycosylation site and not due to changing of amino acid to 
Gln. HeLa cells were transiently transfected with CLN5 wt, N192Q and N192S (patient mutation) 
for 24 h and the WCL was run on gel for western to detect mobility shift. (C) Western of double 
mutant to show gradual size reduction of CLN5. HeLa cells were transfected for 24 h with CLN5 
wt, D279N, N330Q and N192Q +N330Q (double mutant) and the WCL was resolved on a gel for 
western. These data are representative of at least two independent experiments. 
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Figure 2.2- Subcellular localization of CLN5 N-glycosylation mutants. Immunofluorescence 
microscopy of transiently transfected N-glycosylation mutant HeLa cells. HeLa cells were 
seeded on glass coverslips and transfected with CLN5 wt or mutants for 24 h. The cells were 
treated with cycloheximide (50 µg/ml) for 2 h and fixed using 4% formaldehyde and stained for 
CLN5 (mouse α-Myc antibody) , ER marker Calnexin, Lysosome marker Lamp2 or Golgi marker 
Grasp65. The cells were imaged on a Zeiss LSM-5 PASCAL laser scanning confocal microscope. 
(A) CLN5 wt colocalizes partially with lysosomal marker Lamp2 (yellow). N192Q and N227Q 
mutants also partially colocalized with lamp2 (B). (C) N401Q colocalizes with the Golgi marker 
Grasp65 while the other N-glycosylation mutants – N179Q, N252Q, N304Q, and N320Q 
colocalized with ER marker Calnexin (D). N330Q colocalized partially with both Lamp2 and 
Calnexin (E). These data are representative of at least two independent experiments (1000X 
magnification).  
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Figure 2.3- Accumulation of lysosomal-localized CLN5 in rab5A Q79L-induced enlarged 
endosomes. We used a Rab5A mutant (eGFP-Rab5A Q79L) that is defective in its GTPase 
activity and leads to the formation of enlarged endosomes. HeLa cells were seeded on glass 
coverslips and double transfected with eGFP-Rab5A Q79L and CLN5 wt or N-glycosylation 
mutants for 24 h. The cells were chased with CHX for 2 h and fixed using 4% formaldehyde. The 
cells were then stained for CLN5 (mouse α-Myc antibody) and imaged on a Zeiss LSM-5 PASCAL 
laser scanning confocal microscope. (A) CLN5 wt, N192Q and N227Q can be seen to localize 
within the enlarged endosomes. N401Q did not localize with the enlarged endosomes, instead 
colocalizing with Golgi marker Grasp65 (C). N179Q, N252Q, N304Q, and N320Q were not seen 
to localize within the enlarged endosomes indicating that they are stuck in the ER (D). N330Q 
was seen to localize insides and outside the enlarged endosomes (E), consistent with our 
previous results. These data are representative of at least two independent experiments (1000X 
magnification). 
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Table 2.2- Summary of subcellular localization of CLN5 N-glycosylation mutants. Based on the 
imaging data from figure 2.2 and whether CLN5 localizes inside or outside of enlarged 
endosomes (Figure 2.3), N-glycosylation mutants have been categorized into either being in the 
lysosome, ER or Golgi. + indicated positive colocalization, - indicates no colocalization, +/- 
indicates partial colocalization. 
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Figure 2.4- Endo H sensitivity and deglycosylation studies of CLN5. Transiently transfected (24 
h) HeLa  cells were used for these studies. HeLa cells were transfected with CLN5 wt or N-
glycosylation mutants for 24 h and the WCL was used to treat with Endo H enzyme (A) for 3 h  
at 37o C after which it was run on gel and detected by western blotting using mouse α-Myc 
antibody. (B) CLN5 wt transfected HeLa WCL was used for cutting with Endo H, PNGase F for 3 h 
at 37o C along with tunicamycin (1 µg/ml) treated CLN5 transfected WCL. Tunicamycin was 
added to cells at the time of transfection. (C) ER mutants N179Q, N252Q, N320Q, and N304Q 
along with CLN5 wt were used to transfect HeLa cells for 24 h and the WCL was used to cut with 
PNGase F. CLN5 wt tunicamycin sample was also used. These data are representative of at least 
two independent experiments. 
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Figure 2.5- Stability of N-glycosylation deficient CLN5 protein. HeLa cells were transfected with 
CLN5 wt or N-glycosylation mutants for 24 h after which CHX chase was performed for 0, 2 , and 
4 h. The media was changed at the time of CHX chase. Media was collected at 2 and 4 h of CHX 
chase and the pellet was collected at 0, 2, and 4 h time points. The media samples were 
precipitated using ammonium sulfate and run on gel for western. The WCL of pellets was also 
run on gel for western and CLN5 was detected using mouse α-Myc antibody. β-actin was used 
as loading control for the pellet samples. These data are representative of at least two 
independent experiments.  
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Figure 2.6- Subcellular localization of CLN5 patient mutations. HeLa cells were seeded on glass 
coverslips and double transfected using eGFP-Rab5A Q79L and D279N, Y392X or N192S for 24 h 
after which they were chased with CHX for 2 h and fixed using 4% formaldehyde and stained for 
CLN5 using mouse α-Myc antibody. They were then imaged on a Zeiss LSM-5 PASCAL laser 
scanning confocal microscope. D279N did not localize inside of enlarged endosomes and was 
similar to the ER mutants. Y392X also did not localize inside of the enlarged endosomes 
whereas N192S mutant localized to the inside of enlarged endosomes similar to CLN5 wt, 
N192Q, and N227Q mutants (1000X magnification). 
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Supplementary Figure S1- Subcellular localization of CLN5 wt. HeLa cells were seeded 
on glass coverslips and transfected with CLN5 wt for 24 h. The cells were then chased 
with CHX for 2 h and fixed with 100% methanol for 20 min at -20o C. They were then 
stained for CLN5 using rabbit α-CLN5 Ab (IRmII-4) and mouse α-Lamp1.  The cells were 
imaged on a Zeiss LSM-5 PASCAL laser scanning confocal microscope (1000X 
magnification). 
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Supplementary Figure S2 
 
CLUSTAL multiple sequence alignment    
 
H. sapien       ------------------------------------------------------------  
P. troglodytes  ------------------------------------------------------------  
M. mulatta      MVEESEKRSSVLGGAPVTDFRFWFGFGGGCWAGTGQFIKEEAPGLDRILLGARPKRLPGL 60  
B. taurus       ------------------------------------------------------------  
O. aries        ------------------------------------------------------------  
C. familiaris   ------------------------------------------------------------  
C. jacchus      MRALGTLREETT-EARPAVLTTDQGQPEFVFVALGSPELNGKFCCIRFHYLSQTKAPSWT 59  
M. musculus     ------------------------------------------------------------  
R. norvegicus   ------------------------------------------------------------ 
                                                                                
H. sapien       --------------MRRNLRLGPSSGADAQGQGAPRPGLAAPRMLLPPASQASRGSGSTG 46  
P. troglodytes  --------------MRRNLRLLPSSGADAQGQGAPRPGLAAPRMLLPPASQASRGSGSTG 46  
M. mulatta      KSAAAAAGRVRRGVTRRNLRLLPSSGPDXPGWGVPRPGLAAPRMLLPQASQASRGSGSTG 120  
B. taurus       ------------------------------------------------------------  
O. aries        ------------------------------------------------------------  
C. familiaris   ------------------------------------------------------------  
C. jacchus      AKCGSRRGQGAGRSHALEHGSLPNSGASA-GHGGLRPGLAAPRKLHPPASRGAGGAGSTG 118  
R. norvegicus   ------------------------------------------------------------ 
                                                                                
H. sapien       CSLMAQEVDTAQGAEMRRGAGA--ARGRASWCWALALLWLAVVPGWSRVSGIPSRRHWPV 104  
P. troglodytes  CSLMAQEVDTAQGAEMRRGAGA--ARGRASWCWALALLWLAAVQGWSRASGIPSRRHWPV 104  
M. mulatta      CSLMAPELDTAQGAKMRRGAGA--ARGRASWCPAVALLWLAAVPGWPRASGVLSRRHWPV 178  
B. taurus       ---MAQVGSAGPGACGRRGAGAGAGPERTTWRWAPALLWLATA---AAVAGDPSRRQWPV 54  
O. aries        ---MAQAGGAGAGAWGRRGAGAGAGPERAPWRWAPALLWLAAATAAAAAAGDPSRRQWPV 57  
C. familiaris   ---MAQAGSADPGVGGHWAAG----PRCAPWRWALALLWLATA------AGGPSRRQWPV 47  
C. jacchus      GSRMAQEGDTALGVEMRGGAGG--ARGLASRRWALALLFLAAAPGWLPASGSPSRRHWPE 176  
M. musculus     --------------MLRGGPCG------AHWRPALALALLGLAT--ILGASPTSGQRWPV 38  
R. norvegicus   --------------MPRVGPGG------AHWRPALALALLGLAA--TLGASPTSGQRWPV 38 
                                : ..        :    * **  *. .      :.  * ::**    
 
H. sapien       PYKRFDFRPKPDPYCQAKYTFCPTGSPIPVMEGDDDIEVFRLQAPVWEFKYGDLLGHLKI 164  
P. troglodytes  PYKRFDFRPKPDPYCQAKYTFCPTGSPIPVMEGDDDIEVFRLQAPVWEFKYGDLLEHLKI 164  
M. mulatta      PYKRFDSRPKPDPYCQAKYTFCPTGSPIPVMEGDDDIEVFRLQAPVWEFKYGDLLGHLKI 238  
B. taurus       PYKRFSFRPEPDPYCQAKYTFCPTGSPIPVMKDDDVIEVFRLQAPVWEFKYGDLLGHLKI 114  
O. aries        PYKRFSFRPEPDPYCQAKYTFCPTGSPIPVMKDDDVIEVFRLQAPVWEFKYGDLLGHLKI 117  
C. familiaris   PYKRFSFRPEPDPYCQAKYTFCPTGSPIPVMKGDDVIEVFRLQTPVWEFKYGNLLGHLKI 107  
C. jacchus      PYKRFDFRPKPDPYCQAKYTFCPTGSPIPVMKDDDDIEVFRLQAPVWEFKYGDLLGHLKI 236  
M. musculus     PYKRFSFRPKTDPYCQAKYTFCPTGSPIPVMKDNDVIEVLRLQAPIWEFKYGDLLGHFKL 98  
R. norvegicus   PYKRFSFRPKTDPFCQAKYTFCPTGSPIPVMKDNDVIEVLRLQAPVWEFKYGDLLGHFKI 98  
                *****. **:.**:*****************:.:* ***:***:*:******:** *:*:   
 
H. sapien       MHDAIGFRSTLTGKNYTMEWYELFQLGNCTFPHLRPEMDAPFWCNQGAACFFEGIDDVHW 224  
P. troglodytes  MHDAIGFRSTLTGKNYTMEWYELFQLGNCTFPHLRPEMDAPFWCNQGAACFFEGIDDVHW 224  
M. mulatta      MHDAIGFRSTLTGKNYTMEWYELFQLGNCTFPHLRPEMDAPFWCNQGAACFFEGIDDVHW 298  
B. taurus       MHDAIGFRSTLTEKNYTMEWYELFQLGNCTFPHLRPEMNAPFWCNQGAACFFEGIDDSHW 174  
O. aries        MHDAIGFRSTLTEKNYTMEWYELFQLGNCTFPHLRPEMNAPFWCNQGAACFFEGIDDNHW 177  
C. familiaris   MHDAIGFKSTLTGKNYTMEWYELFQLGNCTFPHLRPEMNAPFWCNQGAACFFEGIDDIHW 167  
C. jacchus      MHDAIGFRSTLTGKNYTVEWYELFQLGNCTFPHLRPEMDAPFWCNQGAACFFEGIDDAHW 296  
M. musculus     MHDAVGFRSTLTGKNYTIEWYELFQLGNCTFPHLRPDKSAPFWCNQGAACFFEGIDDKHW 158  
R. norvegicus   MHDAIGFRSTLTGKNYTVEWYELFQLGNCTFPHLRPEVNAPFWCNQGAACFFEGIYDKHW 158 
                ****:**:**** ****:******************: .**************** * **   
 
H. sapien       KENGTLVQVATISGNMFNQMAKWVKQDNETGIYYETWNVKASPEKGAETWFDSYDCSKFV 284  
P. troglodytes  KENGTLVQVATISGNMFNQMAKWVKQDNETGIYYETWNVKASPEKGAETWFDSYDCSKFV 284  
M. mulatta      KENGTLVKVATISGNMFNQMAKWVKQDNETGIYYETWNVKASPEKGAETWFDSYDCSQFV 358  
B. taurus       KENGTLVLVATISGGMFNRMAKWVKQDNETGIYYETWTVQASPERGAERWFESYDCSKFV 234  
O. aries        KENGTLVLVATISGGMFNKMAKWVKQDNETGIYYETWTVQASPKKEAEKWFESYDCSKFV 237  
C. familiaris   KENGTLVLVATISGNTFNQMAKWVKRDNETGIYYETWTVQASPTKGAETWFESYDCSKFV 227  
C. jacchus      KENGTLVQVATISGNMFNKMAKWMKQDNETGIYYETWTVKASPEKGAETWFDSYDCSKFV 356  
M. musculus     KENGTLSVVATISGNTFNKVAEWVKQDNETGIYYETWTVRAGPGQGAQTWFESYDCSNFV 218  
R. norvegicus   KENGTLSLVATVSGNTFNKVAEWVKQDNETGIYYETWTVRASPGKGAQTWFESYDCSNFV 218  
                ******  ***:**. **::*:*:*:***********.*:*.* : *: **:*****:**   
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H. sapien       LRTFNKLAEFGAEFKNIETNYTRIFLYSGEPTYLGNETSVFGPTGNKTLGLAIKRFYYPF 344  
P. troglodytes  LRTFNKLAEFGAEFKNIETNYTRIFLYSGEPTYLGNETSVFGPTGNKTLGLAIKRFYYPF 344  
M. mulatta      LRTFSKLAEFGAEFKNIETNYTRIFLYSGEPTYLGNETSVFGPTGNKTLGLAIKRFYYPF 418  
B. taurus       LRTYEKLAELGADFKKIETNYTRIFLYSGEPTYLGNETSVFGPTGNKTLALAIKKFYYPF 294  
O. aries        LRTYEKLAELGADFKKIETNYTRIFLYSGEPTYLGNETSVFGPTGNKTLALAIKKFYYPF 297  
C. familiaris   LRTYKKLAELGAEFKKIETNYTRIFLYSGEPTYLGNETSIFGPTGNKTLALAIKRFYYPF 287  
C. jacchus      LRTYNKLAEFGAEFKKIETNYTRIFLYSGEPTYLGNETSVFGPTGNKTLALAIKKFYYPF 416  
M. musculus     LRTYKKLAEFGTEFKKIETNYTKIFLYSGEPIYLGNETSIFGPKGNKTLALAIKKFYGPF 278  
R. norvegicus   LRTYEKLAEFGTDFKKIETNYTKIFLYSGEPIYLGNETSIFGPKGNKTLALAIKKFYGPF 278 
                ***:.****:*::**:******:******** *******:***.*****.****:** **   
 
 
 
 
H. sapien       KPHLPTKEFLLSLLQIFDAVIVHKQFYLFYNFEYWFLPMKFPFIKITYEEIPLPIR-NKT 403  
P. troglodytes  KPHLPTKEFLLSLLQIFDAVIVHRQFYLFYNFEYWFLPMKFPFIKITYEEIPLPNR-NKT 403  
M. mulatta      KPHLSTKEFLLNLLQIFDAVIVHREFYLFYNFEYWFLPMKFPFIKITYEEIPLPNK-NKT 477  
B. taurus       KPHLSTKEFLLSLLQIFDAVVIHREFYLFYNFEYWFLPMKYPFIKITYEEIPLPNRKNRT 354  
O. aries        KPHLSTKEFLLSLLQIFDAVVIHREFYLFYNFEYWFLPMKSPFIKITYEEIPLPNRKNRT 357  
C. familiaris   KPHLSTKEFLLSILQIFDAVIIHREFYLFYNFEYWFLPMKFPFIKITYEEIPLPKR-NET 346  
C. jacchus      KPHLSTKEFLLSLLQIFDAVIVHRQFYLFYNFEYWFLPMKFPFIRITYEEIPLPKR-NKT 475  
M. musculus     RPYLSTKDFLMNFLKIFDTVIIHRQFYLFYNFEYWFLPMKPPFVKITYEETPLPTR-HTT 337  
R. norvegicus   KRYSSTKDFLLNFLKIFDTVIMHREFYLFYNFEYWFLPMKPPFVKITYEETPLPTQ-HTT 337 
                : : .**:**:.:*:***:*::*::*************** **::***** *** : : *   
 
H. sapien       LSGL-------- 407  
P. troglodytes  LSGL-------- 407  
M. mulatta      LSGL-------- 481  
B. taurus       LSGL-------- 358  
O. aries        LSGL-------- 361  
C. familiaris   LSGL-------- 350  
C. jacchus      LSARHGSSHL-- 485  
M. musculus     FTDL-------- 341  
R. norvegicus   FTDL-------- 341   
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Supplementary Figure S2- Sequence alignment of CLN5. Alignment of mammalian CLN5 
protein sequences.  Yellow highlights indicate conserved N-glycosylation sites among different 
species while the green highlight indicates the N-glycosylation site corresponding to human 
N401, which is not conserved in rodents such as M. musculus and R. norvegicus. Sequences 
used in this alignment: H. sapien    NP_006484, P. troglodytes XP_509687, M. mulatta 
XP_001086029, B. taurus DAA23821, O. aries        NP_001076064, C. familiaris NP_001011556, 
C. jacchus XP_002742639, M. musculus AAI41315, and R. norvegicus NP_001178618. 
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DISCUSSION AND FUTURE PROSPECTIVES 
The spectrum of mutations that have been recently identified to result in NCL has grown 
steadily and what was once considered to be a disease limited to a specific population is now 
known to have a diverse ethnic spread. Many genes have been discovered that are known to 
cause NCL. There is an immense effort going on to find ways to cure or prevent NCL. The 
progress of drug discovery for NCL has been hindered by the fact that function of most NCL 
proteins is unknown. It is imperative to characterize a protein before a deeper understanding of 
its function can be comprehended. CLN5 we known is one such protein whose function remains 
unknown. We have studied the importance of N-glycosylation on the transport and stability of 
CLN5 here. N-glycosylation is an important modification that takes place co/post-
translationally. Although it is not the only kind of modification, it is still an important one as it is 
known to aid in the proper folding and functioning of proteins. In addition N-glycosylation also 
protects the protein from other hydrolases and unfavorable environments. We have shown 
that all the eight putative N-glycosylation sites are used in vivo. Since all the sites are used, it 
suggests that all sites play a role in either folding, stability and/or trafficking of CLN5, although 
it is possible that one or more N-glycosylation sites are paramount for CLN5 function and/or 
transport. This study will help in understanding the role of CLN5 in NCL better. It will aid later 
studies on CLN5 as it expands on some of the basic characterization of CLN5. 
 Mass spectrometry and bioinformatics studies have predicted that, of the eight 
potential N-glycosylation sites, the last three - Asn320, 330 and 401 potentially have a M6P tag. 
M6P is essential for the recognition by M6PR to transport cargo to the endosomes. Some LSD 
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result due to faulty transport of proteins. I-cell disease is one of them where there a defect in 
the enzyme that is involved in the addition of M6P tag. In I-cell disease, lysosomal hydrolases 
and other lysosomal proteins that are normally transported via the M6P pathway to the 
lysosomes end up being secreted out of the cell as they do not have an M6P tag anymore. Of 
the three predicted N-glycosylation sites with an M6P tag in CLN5, our studies indicate that 
Asn401 to be a prime candidate in the transport of CLN5 by M6P pathway. We feel Asn401 to 
be the prime candidate because mutating Asn320 to Gln results in the protein being retained in 
the ER and as such it is difficult to assess its role in M6P pathway. N330Q mutant was able to 
locate to the lysosomes, but it was also seen to be retained in the ER. Thus, Asn330 does not 
seem to play an integral role in the M6P mediated transport of CLN5 to the lysosomes. Asn401 
on the other hand, when mutated to Gln caused it to be retained mostly in the Golgi and was 
not observed in the ER or lysosomes. CHX chase studies also showed that the N401Q mutant 
gets secreted out into the media very early and is more prominent than CLN5 wt. The loss of 
M6P tag is known to result in lysosomal proteins being secreted out in I-cell disease, indicating 
that Asn401 might play a similar role in targeting CLN5 to the endosomes/lysosomes. Although 
studies have shown CLN5 to utilize M6P independent pathways to reach the lysosomes, these 
studies were done in mice and interestingly, mouse CLN5 lacks the Asn401 N-glycosylation site. 
It is possible that there are other mechanisms that compensate for the loss of Asn401 site in 
mouse. From our studies the importance of Asn401 in human CLN5 transport cannot be 
ignored.  Future studies can focus on elucidating the role of Asn401 in the transport of CLN5 to 
the endosomes via the M6P pathway. It is not known if M6P pathway is the only pathway 
utilized by human cells for the trafficking of CLN5. One way to elucidate the role of M6P in CLN5 
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trafficking would be to use M6PR knockout cells or use siRNA against M6PR and look at the 
subcellular localization of human CLN5. It is possible that in the absence of M6PR, CLN5 could 
utilize other adaptors/mechanisms/pathways to reach the lysosomes (e.g., LIMP and Sortilin). A 
similar modus operandi of knocking out or silencing these transport adaptors along with M6PR 
can be employed to look at CLN5 localization.  
Among the known CLN5 mutations that cause NCL, N192S is on one of the N-
glycosylation sites. This mutant localizes to the lysosome. Our studies also show that abrogating 
the N-glycosylation site at Asn192 does not affect the localization of CLN5 and it ends up in the 
lysosome. The fact that ablation of this site is known to cause NCL but does not affect the 
localization is an important indication that this site is essential for the proper functioning of 
CLN5. It does not seem to have a very important role in the transport or proper folding of CLN5. 
This mutation (N192S) can be used as a tool to study the functioning of CLN5 in the future, 
along with the other mutations of N-glycosylation in CLN5 that are able to reach the lysosomes 
(N192Q and N227Q). Since CLN5 is known to interact with other NCL proteins, it would be 
interesting to look at the interaction (or loss of) of CLN5 N192S mutant along with N192Q and 
N227Q. It is possible that abrogation of N-glycosylation at Asn192 renders CLN5 unable to bind 
to its normal partners resulting in NCL. Co-IP experiments of CLN5 wt and N192S mutant will 
help in clarifying this point.  
  CLN5 is a highly glycosylated protein and removal of the glycosylation (Endo H or 
PNGase F digestion) causes the size of the CLN5 protein to drop drastically. We have seen that 
PNGase F digested CLN5 runs slightly higher than the tunicamycin treated CLN5. This hints at 
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the presence of other modifications on CLN5. CLN5 could be O-glycosylated, phosphorylated, 
sulfated or lipoylated. Digesting CLN5 with O-glycosidase alone or in combination with PNGase 
F would be a means of figuring the extra modification on CLN5. Another outlet would be to 
treat CLN5 with a general phosphatase alone or in combination with PNGase F for the same 
purpose as above.  
  Clearly N-glycosylation plays an important role in the proper functioning, 
transport and stability of CLN5 and this study corroborates these facts. This study adds to the 
basic understanding of CLN5. Having said that, there is still immense scope for understanding 
CLN5 protein and how it functions in NCL disease.  
 
